Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj) Patent Expiration, LOE Window & CMS Spending

Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj) by Johnson & Johnson: Off-Patent Genericized (AB Competition), 0 AB generics, $269.7M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$269.7M
2024 Medicare Part D Spend$102.7M
2024 Medicaid Spend$166.9M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 26.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.